Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the members of its executive management team will participate in a fireside chat at the Raymond James 42nd Annual Institutional Investors Conference at 2:10 pm ET on Wednesday, March 3, 2021. To access a live webcast of the presentation, please click here. An archived webcast of the presentation will be available for 90 days on the Events and Presentations section of the ...
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) (the “Company”) today announced that in connection with its previously announced public offering of its common stock, the underwriters partially exercised and closed their over-allotment option to purchase an additional 485,000 shares of the Company’s common stock, offered at a price of $5.75 per share to the public. The Company received approximately $2.8 million in additional gross proceeds ...
Upgrades For Sealed Air Corp (NYSE:SEE), Seaport Global upgraded the previous rating of Neutral to Buy. Sealed Air earned $0.89 in the fourth quarter, compared to $0.78 in the year-ago quarter. At the moment, the stock has a 52-week-high of $47.90 and a 52-week-low of $17.06. Sealed Air closed at $45.42 at the end of the last trading period. For Blackbaud Inc (NASDAQ:BLKB), Benchmark upgraded the previous rating of Hold to Buy. For the fourth quarter, Blackbaud had an EPS of $0.85, compared to y...
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented positive pre-clinical data from its Marzeptacog alfa (activated) – MarzAA, program, the Company’s subcutaneously (SQ) administered next-generation engineered activated coagulation Factor VII (FVIIa) for the treatment of episodic bleeding that is entering a Phase 3 registration trial. The data were presented by Tom Knudsen, D.V.M., Ph.D., vice president of translational researc...
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) (the “Company”) today announced the closing of an underwritten public offering of 8,700,000 shares of its common stock, offered at a price of $5.75 per share to the public. The gross proceeds to the Company from this offering were approximately $50 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. All of the shares in...
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO (the “Company”) today announced the pricing of an underwritten public offering of 8,700,000 shares of its common stock, offered at a price of $5.75 per share to the public. Additionally, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,305,000 shares of its common stock. All of the shares in the offering are being offered by the Company. The offering is...
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that it is offering shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, Catalyst expects to grant the underwriters of the offering a 30-day option to purchase up to ...